Augmented cytotoxicity of estramustine and etoposide combination in hormone refractory prostate cancer cell lines and association with TGF modulation

被引：0
|
作者：
LN Türkeri
O Ayaz
M Özyürek
A Akdas
机构：
[1] ‘Ergun Özalp’ Research Laboratory,Department of Urology
[2] Marmara University School of Medicine,undefined
来源：
Prostate Cancer and Prostatic Diseases | 1999年 / 2卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：S33 / S33
相关论文
共 50 条
  • [41] Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer
    Matsumoto, Akihiro
    Inoue, Atsushi
    Yokoi, Satoshi
    Nozumi, Kazuyoshi
    Miyazaki, Kanetaka
    Hosoki, Shigeru
    Nagata, Maki
    Yamaguchi, Kunio
    INTERNATIONAL JOURNAL OF UROLOGY, 2009, 16 (08) : 687 - 691
  • [42] Dramatic decline in prostate-specific antigen by withdrawal of estramustine phosphate in hormone refractory prostate cancer
    Kobayashi, Mizuki
    Kuramoto, Hiroshi
    Ota, Junichiro
    Fujimoto, Naohiro
    INTERNATIONAL JOURNAL OF UROLOGY, 2006, 13 (07) : 1019 - 1021
  • [43] TREATMENT OF ADVANCED HORMONE-REFRACTORY PROSTATE CARCINOMA WITH A COMBINATION OF ETOPOSIDE, PIRARUBICIN AND CISPLATIN
    NAITO, S
    UEDA, T
    KOTOH, S
    KUMAZAWA, J
    ITOH, K
    SAGIYAMA, K
    OMOTO, T
    ANDOH, S
    HASEGAWA, Y
    FUJISAWA, Y
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1995, 35 (03) : 225 - 229
  • [44] Enhanced cytotoxicity and apoptosis by thymoquinone in combination with zoledronic acid in hormone- and drug-resistant prostate cancer cell lines
    Dirican, Ahmet
    Erten, Cigdem
    Atmaca, Harika
    Bozkurt, Emir
    Kucukzeybek, Yuksel
    Varol, Umut
    Tarhan, Mustafa Oktay
    Karaca, Burcak
    Uslu, Ruchan
    JOURNAL OF BUON, 2014, 19 (04): : 1055 - 1061
  • [45] Monthly paclitaxel and carboplatin with oral estramustine phosphate in patients with hormone-refractory prostate cancer
    Segawa T.
    Kamoto T.
    Kinoshita H.
    Kunishima Y.
    Yoshimura K.
    Ito A.
    Takahashi T.
    Higashi S.
    Nakamura E.
    Nishiyama H.
    Ito N.
    Yamamoto S.
    Habuchi T.
    Ogawa O.
    International Journal of Clinical Oncology, 2005, 10 (5) : 333 - 337
  • [46] A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer
    Berry, William
    Friedland, David
    Fleagle, John
    Jackson, Dori
    Ilegbodu, Des
    Boehm, Kristi A.
    Asmar, Lina
    CLINICAL GENITOURINARY CANCER, 2006, 5 (02) : 131 - 137
  • [47] EFFICACY AND SAFETY OF THE ASSOCIATION OF PACLITAXEL AND ESTRAMUSTINE WITH ZOLENDRONIC ACID, IN METASTATIC HORMONE-REFRACTORY PROSTATE CARCINOMA
    Chiesa, M. Dalla
    Negri, F.
    Bergonzi, C.
    Musolino, A.
    Perrone, A.
    Potenzoni, D.
    Cantoni, C.
    Di Giovanni, M.
    Donati, G. V.
    Passalacqua, R.
    ANNALS OF ONCOLOGY, 2004, 15 : 97 - 97
  • [48] A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer
    Lin, Amy M.
    Rini, Brian I.
    Derynck, Mika K.
    Weinberg, Vivian
    Park, Margaret
    Ryan, Charles J.
    Rosenberg, Jonathan E.
    Bubley, Glenn
    Small, Eric J.
    CLINICAL GENITOURINARY CANCER, 2007, 5 (05) : 323 - 328
  • [49] Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: A single-center experience
    Boehmer, A
    Anastasiadis, AG
    Feyerabend, S
    Nagele, U
    Kuczyk, M
    Schilling, D
    Corvin, S
    Merseburger, AS
    Stenzl, A
    ANTICANCER RESEARCH, 2005, 25 (6C) : 4481 - 4486
  • [50] Safety and efficacy of docetaxel, estramustine phosphate and hydrocortisone in hormone-refractory prostate cancer patients
    Nakagami, Yoshihiro
    Ohori, Makoto
    Sakamoto, Noboru
    Koga, Shoji
    Hamada, Riu
    Hatano, Tadashi
    Tachibana, Masaaki
    INTERNATIONAL JOURNAL OF UROLOGY, 2010, 17 (07) : 629 - 634
12345